Latest news
25 items- 13D/GSEC Form SC 13D filed by AIkido Pharma Inc.SC 13D - Dominari Holdings Inc. (0000012239) (Subject)
- 13D/GSEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)
- INSIDERWool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERDevall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERWool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERHayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- SECAIkido Pharma Inc. filed SEC Form 8-K: Leadership Update8-K - Dominari Holdings Inc. (0000012239) (Filer)
- INSIDERHayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERWool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERDevall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERDevall Christopher Franklin bought $2,259 worth of shares (1,000 units at $2.26), increasing direct ownership by 5% to 22,033 units (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERWool Kyle Michael bought $2,200 worth of shares (1,000 units at $2.20) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERHayes Anthony bought $5,965 worth of shares (2,804 units at $2.13) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERWool Kyle Michael bought $4,103 worth of shares (2,000 units at $2.05) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERHayes Anthony bought $4,916 worth of shares (2,500 units at $1.97) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERSEC Form 3 filed by new insider Haug Kyle3 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERHayes Anthony bought $4,825 worth of shares (2,500 units at $1.93) (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- SECAIkido Pharma Inc. filed SEC Form 8-K: Leadership Update8-K - Dominari Holdings Inc. (0000012239) (Filer)
- SECSEC Form 10-Q filed by AIkido Pharma Inc.10-Q - Dominari Holdings Inc. (0000012239) (Filer)
- SECAIkido Pharma Inc. filed SEC Form 8-K: Other Events8-K - Dominari Holdings Inc. (0000012239) (Filer)
- SECSEC Form 8-A12B filed by AIkido Pharma Inc.8-A12B - Dominari Holdings Inc. (0000012239) (Filer)
- SECAIkido Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Dominari Holdings Inc. (0000012239) (Filer)
- SECAIkido Pharma Inc. filed SEC Form 8-K: Leadership Update8-K - Dominari Holdings Inc. (0000012239) (Filer)
- INSIDERWay George was granted 96,311 shares (SEC Form 4)4 - Dominari Holdings Inc. (0000012239) (Issuer)
- INSIDERSEC Form 3 filed by new insider Way George3 - Dominari Holdings Inc. (0000012239) (Issuer)
AIKI FAQ
6 questionsWhat does AIkido Pharma Inc. do?
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement...Where does AIKI stock trade?
AIkido Pharma Inc. (AIKI) is listed on NASDAQ.What sector and industry is AIKI in?
AIkido Pharma Inc. operates in the Consumer Discretionary sector, Specialty Chemicals industry.What are analysts saying about AIKI?
AIkido Pharma Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $200.00 price target on 2021-10-11. Recent price targets cluster around $200.00.What companies are similar to AIKI?
Notable peers in the same industry include KVUE (Kenvue Inc.), CSL (Carlisle Companies Incorporated), CLX (Clorox Company), UNVR (Univar Solutions Inc.), DSEY (Diversey Holdings Ltd.). Compare AIKI side-by-side with any of them on Quantisnow.How can I track AIKI on Quantisnow?
Quantisnow aggregates AIkido Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AIKI to receive live email and push alerts on every new disclosure.